Partnerships, Licensing, Investments and M&A Deals and Trends for February 2015 in Pharmaceuticals

Publisher Name :
Date: 31-Mar-2015
No. of pages: 102
Inquire Before Buying

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for February 2015 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in February 2015. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals deals database and primary and secondary research.

Scope


  • Analysis of the market trends for the pharmaceutical industry in the global arena.

  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

  • Analysis of partnership and licensing deals based on clinical stage of development of products.

  • Summary of the pharmaceutical deals globally in the six months.

  • Information on the top deals happened in the pharmaceutical industry.

  • Geographies covered include North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.


Reasons to buy

  • Enhance your decision making capability in a more rapid and time sensitive manner.

  • Find out the major deal performing segments for investments in your industry.

  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

  • Identify companies that are aggressively looking to raise capital in the market

  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

  • Identify growth segments and opportunities in each region within the industry.

  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Partnerships, Licensing, Investments and M&A Deals and Trends for February 2015 in Pharmaceuticals

Table of Contents

1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 9

2 Pharmaceuticals & Healthcare, Global, Deal Summary 12
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, February 2015 12
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, February 2015 14
2.2.1 Pfizer to Acquire Hospira for USD17 Billion 14
2.2.2 Valeant Pharma to Acquire Salix Pharma 15
2.2.3 Merck Completes Public Offering of Notes for USD8 Billion 17
2.2.4 Actavis Raises USD5.06 Billion in Public Offering of Preferred Shares 18
2.2.5 Actavis Raises USD4.18 Billion in Public Offering of Shares 19
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, February 2015 20
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, February 2015 21

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 22
3.1 Pharmaceuticals & Healthcare, Global, M&A, January 2015 22
3.1.1 Top M&A Deals in February 2015 23
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, September 2014 - February 2015 24
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, February 2015 26
3.2.1 Top Equity Offering Deals in February 2015 27
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, September 2014 - February 2015 28
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, February 2015 30
3.3.1 Top PE/VC Deals in February 2015 31
3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, February 2015 32
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, February 2015 34
3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, September 2014-February 2015 36
3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, September 2014-February 2015 37

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, February 2015 38
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, February 2015 38
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, September 2014 - February 2015 40
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), February 2015 42
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, February 2015 43
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), September 2014 - February 2015 44
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, September 2014 - February 2015 46
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), September 2014 - February 2015 47
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), September 2014 - February 2015 49

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, February 2015 51
5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, February 2015 51
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), February 2015 53
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, February 2015 54
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, February 2015 55
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, February 2015 55
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), September 2014 - February 2015 56
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), September 2014 - February 2015 58
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), September 2014 - February 2015 60
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), September 2014 - February 2015 62

6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 64
6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, February 2015 64
6.1.1 Oncology - Deals of the Month 66
6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, February 2015 67
6.2.1 Central Nervous System - Deals of the Month 68
6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, February 2015 70
6.3.1 Infectious Diseases - Deals of the Month 71
6.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, February 2015 73
6.4.1 Cardiovascular - Deals of the Month 74
6.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, February 2015 76
6.5.1 Immunology - Deal of the Month 77
6.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, February 2015 79
6.6.1 Gastrointestinal - Deals of the Month 80
6.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, February 2015 81
6.7.1 Metabolic Disorders - Deal of the Month 82

7 Deal Summary by Geography 83
7.1 Pharmaceuticals & Healthcare, North America Deals, February 2015 83
7.1.1 North America - Deals of the Month 84
7.2 Pharmaceuticals & Healthcare, Europe, Deals, February 2015 86
7.2.1 Europe - Deals of the Month 87
7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, February 2015 89
7.3.1 Asia-Pacific - Deals of the Month 90
7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, February 2015 92
7.4.1 Rest of the World - Deals of the Month 93

8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 95
8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, September 2014 - February 2015 95
8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, September 2014 - February 2015 97

9 Further Information 99
9.1 Methodology 99
9.2 About GlobalData 100
9.3 Disclosure information 101
9.4 Disclaimer 101

List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 13
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, January 2015 14
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), February 2015 21
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 23
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, February 2015 23
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2014 - February 2015 25
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 27
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, February 2015 27
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 29
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 31
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, February 2015 31
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, September 2014 - February 2015 33
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), February 2015 35
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 36
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, September 2014 - February 2015 37
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 39
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 41
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2014 - February 2015 43
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), February 2015 43
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2014 - February 2015 45
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2014 - February 2015 48
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), September 2014 - February 2015 50
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 52
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), September 2014 - February 2015 54
Table 25: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, February 2015 54
Table 26: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, February 2015 55
Table 27: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, February 2015 55
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 57
Table 29: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), February 2015 59
Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2014 - February 2015 61
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), February 2015 63
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 65
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 68
Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 71
Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 74
Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 77
Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 80
Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 82
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 84
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 87
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 90
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 93
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 96
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 98

List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 12
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%),February 2015 20
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), February 2015 21
Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 22
Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2014 - February 2015 24
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 26
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 28
Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 30
Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2014 - February 2015 32
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), February 2015 34
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), February 2015 35
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 36
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 38
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 40
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2014 - February 2015 42
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2014 - February 2015 44
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2014 - February 2015 46
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2014 - February 2015 47
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), September 2014 - February 2015 49
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 51
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2014 - February 2015 53
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 56
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2014 - February 2015 58
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, September 2014 - February 2015 60
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), September 2014 - February 2015 61
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), February 2015 62
Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 64
Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 67
Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 70
Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 73
Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 76
Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 79
Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 81
Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 83
Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 86
Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 89
Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 92
Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 95
Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), September 2014 - February 2015 97

  • Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2015
    Published: 04-May-2015        Price: US 1500 Onwards        Pages: 140
    GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2015" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q1 2015. The report ......
  • Partnerships, Licensing, Investments and M&A Deals and Trends for 2014 in Pharmaceuticals
    Published: 01-May-2015        Price: US 3500 Onwards        Pages: 172
    GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for 2014 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2014. The report port......
  • Partnerships, Licensing, Investments and M&A Deals and Trends for March 2015 in Pharmaceuticals
    Published: 01-May-2015        Price: US 1000 Onwards        Pages: 104
    GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for March 2015 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2015. The......
  • Finding Biopharma Licensing and Collaboration Partners
    Published: 01-Apr-2015        Price: US 1495 Onwards        Pages: 172
    Current Partnering's Finding Biopharma Licensing and Collaboration Partners provides a comprehensive overview of all the steps required to identify and secure potential partnering opportunities either for an in-licensing or out-licensing activity. The report takes the reader through the practical steps required to prepare for partnering, prepare supporting materials, identify and shortlist potential partners and opportunities, identifying and contacting the right person in the partner company......
  • Top 50 Big Biotech Partnering and M&A Deal Trends
    Published: 01-Apr-2015        Price: US 2495 Onwards        Pages: 529
    The Top 50 Big Biotech Partnering and M&A Deal Trends report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big biotech companies. Top 50 Big Biotech Partnering and M&A Deal Trends provides the user with the following key benefits: Detailed partnering activity profiles for each of the top 50 big biotech companies Over 300 charts showing a company's dealmaking activity s......
  • Top 50 Big Pharma Partnering and M&A Deal Trends
    Published: 01-Apr-2015        Price: US 3495 Onwards        Pages: 798
    The Top 50 Big Pharma Partnering and M&A Deal Trends report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies. Top 50 Big Pharma Partnering and M&A Deal Trends provides the user with the following key benefits: Detailed partnering activity profiles for each of the top 50 big pharma companies Over 300 charts showing a company's dealmaking activity since......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs